Integrase inhibitors: current protagonists in antiretroviral therapy.

Abstract

Since HIV was identified as the etiological agent of AIDS, there have been significant advances in antiretroviral therapy (ART) that has reduced morbidity/mortality. Still, the viral genome's high mutation rate, suboptimal ART regimens, incomplete adherence to therapy and poor control of the viral load generate variants resistant to multiple drugs. Licensing over 30 anti-HIV drugs worldwide, including integrase inhibitors, has marked a milestone since they are potent and well-tolerated drugs. In addition, they favor a faster recovery of CD4+ T cells. They also increase the diversity profile of the gut microbiota and reduce inflammatory markers. All of these highlight the importance of including them in different ART regimens.

• Authors: John D Loaiza, Mateo Chvatal-Medina, Juan C Hernandez, Maria T Rugeles
• Journal: Immunotherapy (Immunotherapy) Vol. 15 Issue 17 Pg. 1477-1495 (12 2023) ISSN: 1750-7448 [Electronic] England
• PMID: 37822251 (Publication Type: Journal Article, Review, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-HIV Agents
• Integrase Inhibitors

Topics

• Humans
• Anti-HIV Agents (pharmacology, therapeutic use)
• Integrase Inhibitors (therapeutic use)
• HIV Infections (drug therapy)